Eutilex Submits Clinical Trial Application for Immuno-Oncology Drug EU101 Phase 1/2 Study

[Asia Economy Reporter Oh Ju-yeon] Eutilex announced on the 21st that it has submitted a clinical trial application for Phase 1/2 of the immuno-oncology drug EU101 to the U.S. Food and Drug Administration (FDA). The company explained, "EU101 activates and proliferates killer T cells of the immune system that attack cancer in patients with advanced solid tumors, and is expected to minimize treatment side effects, reduce and control tumor size, extend progression-free survival, extend overall survival, and improve quality of life."